Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the period of October 2022. The report serves to lodge the Company's 2022 Annual Report and Corporate Governance Statement with the Australian Securities Exchange (ASX) for the financial year ended June 30, 2022.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached 2022 Annual Report (Exhibit 99.1), which is referenced but not detailed in this summary document.
Material Changes
The filing text does not provide data to compare current performance against prior periods. Material changes would be detailed in the attached Annual Report.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, future guidance, specific risk factors, or details on contingencies. The Corporate Governance Statement (Exhibit 99.3) and Annual Report (Exhibit 99.1) are the sources for this information.
Investor Verification Checklist
- Verify the correct registrant name is Bionomics Limited, not Neuphoria Therapeutics Inc.
- Review Exhibit 99.1 (2022 Annual Report) for actual financial performance data for the year ended June 30, 2022.
- Examine Exhibit 99.2 (ASX Appendix 4G) for details on share capital and related party transactions.
- Consult Exhibit 99.3 for the Company's corporate governance framework and risk management policies.